Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Non-cash Items of -$483.9 million for Q2 2026, down 95.75% year-over-year from -$11.4 billion in Q2 2025, and down 237.59% quarter-over-quarter from $351.7 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Non-cash Items history runs 18 years deep, the most recent figure standing at -$483.9 million for Q2 2026.
- In Q2 2026, Non-cash Items fell 95.75% year-over-year to -$483.9 million; the TTM figure through Jun 2026 stood at $352.6 million (up 23.76% YoY), while the FY2025 annual figure was $474.0 million, up 5900.0% from the prior year.
- Non-cash Items for Q2 2026 stood at -$483.9 million, down from $351.7 million in the prior quarter.
- The five-year high for Non-cash Items was $1.1 billion in Q1 2022, with the low at -$1.1 billion in Q2 2024.
- The 5-year median for Non-cash Items is $132.6 million (2023), against an average of $92.6 million.
- Peak annual rise in Non-cash Items reached 593.71% in 2024, while the deepest fall reached 2096.85% in 2024.
- Regeneron Pharmaceuticals' Non-cash Items stood at $522.8 million in 2022, then tumbled by 113.37% to -$69.9 million in 2023, then jumped by 593.71% to $345.1 million in 2024, then retreated by 5.51% to $326.1 million in 2025, then tumbled by 248.39% to -$483.9 million in 2026.
- Business Quant data shows REGN's Non-cash Items at -$483.9 million in Q2 2026, $351.7 million in Q1 2026, and $326.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -483.90 Mn |
| Jun 30, 2026 | -483.90 Mn |
| Mar 31, 2026 | 351.70 Mn |
| Mar 31, 2026 | 351.70 Mn |
| Dec 31, 2025 | 326.10 Mn |
| Dec 31, 2025 | 326.10 Mn |
| Sep 30, 2025 | 158.70 Mn |
| Sep 30, 2025 | 158.70 Mn |
| Jun 30, 2025 | -247.20 Mn |
| Jun 30, 2025 | -247.20 Mn |
| Mar 31, 2025 | 236.40 Mn |
| Mar 31, 2025 | 236.40 Mn |
| Dec 31, 2024 | 345.10 Mn |
| Dec 31, 2024 | 345.10 Mn |
| Sep 30, 2024 | -49.40 Mn |
| Sep 30, 2024 | -49.40 Mn |
| Jun 30, 2024 | -1.08 Bn |
| Jun 30, 2024 | -1.08 Bn |
| Mar 31, 2024 | 790.50 Mn |
| Mar 31, 2024 | 790.50 Mn |